Exencial Wealth Advisors LLC Invests $393,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Key Points

• Exencial Wealth Advisors LLC invested approximately $393,000 to acquire 2,613 shares of Charles River Laboratories International, Inc. in the first quarter.
• Institutional investors collectively own 98.91% of Charles River Laboratories, indicating strong institutional interest in the company.
• Analysts have recently upgraded their ratings on the stock, with a consensus target price of $175.69 and several firms setting price targets as high as $179.00.

Exencial Wealth Advisors LLC acquired a new position in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 2,613 shares of the medical research company's stock, valued at approximately $393,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. J. Safra Sarasin Holding AG raised its stake in shares of Charles River Laboratories International by 6.6% during the first quarter. J. Safra Sarasin Holding AG now owns 8,783 shares of the medical research company's stock worth $1,322,000 after buying an additional 540 shares during the last quarter. Malaga Cove Capital LLC raised its stake in shares of Charles River Laboratories International by 10.1% during the first quarter. Malaga Cove Capital LLC now owns 2,022 shares of the medical research company's stock worth $304,000 after buying an additional 185 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of Charles River Laboratories International by 11.5% during the first quarter. PNC Financial Services Group Inc. now owns 15,926 shares of the medical research company's stock worth $2,397,000 after buying an additional 1,648 shares during the last quarter. Natixis Advisors LLC raised its stake in shares of Charles River Laboratories International by 8.4% during the first quarter. Natixis Advisors LLC now owns 85,048 shares of the medical research company's stock worth $12,801,000 after buying an additional 6,609 shares during the last quarter. Finally, NorthRock Partners LLC bought a new stake in shares of Charles River Laboratories International during the first quarter worth approximately $275,000. 98.91% of the stock is owned by institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 500 shares of the business's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president directly owned 19,513 shares of the company's stock, valued at approximately $2,837,385.33. The trade was a 2.50% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders have sold 1,040 shares of company stock valued at $152,423. 1.30% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

CRL has been the subject of a number of recent research reports. TD Cowen raised shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price target for the company in a research note on Wednesday, May 14th. Robert W. Baird boosted their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a report on Thursday, May 8th. Wall Street Zen upgraded shares of Charles River Laboratories International from a "hold" rating to a "strong-buy" rating in a report on Saturday. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Finally, Barclays boosted their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a report on Thursday. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and a consensus target price of $175.69.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $149.07 on Friday. The company has a fifty day simple moving average of $155.55 and a 200 day simple moving average of $149.36. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $230.02. The company has a current ratio of 1.36, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69. The company has a market cap of $7.34 billion, a P/E ratio of -112.08, a PEG ratio of 4.96 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.62. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. Charles River Laboratories International's revenue was up .6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.80 EPS. Sell-side analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.